Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole.

Abstract

Disseminated Trichosporon infection in neutropenic patients carries a poor prognosis. Clinical evidence on the use of voriconazole for this infection is limited. The authors report a case of Trichosporon asahii fungemia refractory to liposomal amphotericin B treatment in a boy with acute lymphoblastic leukemia, which resolved after the addition of voriconazole. Both voriconazole and amphotericin B exhibited low minimal inhibitory concentrations and minimal fungicidal concentrations, and their combination was indifferent in vitro. The use of voriconazole for the treatment of trichosporonosis in patients with hematologic malignancies deserves further study.

• Authors: Charalampos Antachopoulos, Eugenia Papakonstantinou, John Dotis, Evangelia Bibashi, Maria Tamiolaki, Dimitrios Koliouskas, Emmanuel Roilides
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 27 Issue 5 Pg. 283-5 (May 2005) ISSN: 1077-4114 [Print] United States
• PMID: 15891566 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antifungal Agents
• Pyrimidines
• Triazoles
• Amphotericin B
• Voriconazole

Topics

• Adolescent
• Amphotericin B (therapeutic use)
• Antifungal Agents (therapeutic use)
• Fungemia (drug therapy)
• Humans
• Male
• Mycoses (drug therapy)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Pyrimidines (therapeutic use)
• Treatment Outcome
• Triazoles (therapeutic use)
• Trichosporon (classification, isolation & purification)
• Voriconazole